Level 1 - Absolute Beginner

Scientists have found that a common medicine for asthma may also fight cancer. The medicine is called montelukast. Millions of people use it every day to help with breathing problems.

Cancer is a disease where cells in the body grow in the wrong way. Some cancers are very hard to treat. One of the hardest cancers to treat is called triple-negative breast cancer.

Scientists at Northwestern University in the US did experiments with mice. They gave montelukast to mice that had cancer. The drug helped the mice's immune system fight the cancer better.

This is very exciting news. The drug is already safe for humans. This means it could move to tests with people faster than a brand new drug. Scientists are now planning those tests.

asthma

a condition that makes it hard to breathe because the airways become narrow and swollen

drug

a medicine used to treat or prevent illness

cancer

a disease in which cells in the body grow in an uncontrolled way and can damage healthy tissue

immune system

the body's natural defense system that fights infections and disease

treatment

a way of dealing with an illness using medicine, surgery, or other methods

experiment

a scientific test done to find out if an idea is true

tumor

an abnormal lump of tissue that forms when cells grow in an uncontrolled way

clinical trial

a study that tests a medical treatment on real patients to see if it is safe and effective

Level 2 - Elementary

A team of scientists at Northwestern University in Chicago has discovered that montelukast, a widely prescribed asthma and allergy drug, may help the immune system fight aggressive cancers. The research was published in the journal Nature Cancer and has attracted attention because montelukast is already approved by the FDA, meaning potential new cancer treatments could reach patients more quickly.

The scientists focused on a molecule inside the body called CysLTR1. This molecule is well-known for causing inflammation in asthma patients. However, the team found that many cancers use this same molecule to protect themselves from the immune system. Tumors increase the number of a type of white blood cell called neutrophils, which then help the cancer grow instead of fighting it.

When the scientists blocked CysLTR1 using montelukast in mouse studies, the immune system was able to fight the tumors more effectively. Tumor growth slowed significantly, the mice survived longer, and their immune response to immunotherapy treatments improved. The results were especially strong in triple-negative breast cancer, one of the most difficult cancers to treat because it does not respond to many standard therapies.

The researchers believe montelukast could be combined with existing immunotherapy drugs to create more powerful cancer treatment combinations. Because the drug is already approved and widely available, clinical trials in human patients could begin relatively quickly. The team is now designing those trials to test whether the findings in mice can be reproduced in people.

inflammation

a response by the body's immune system that causes swelling, redness, and heat, often in response to injury or disease

molecule

a very small particle made of two or more atoms joined together; molecules carry out important functions inside living cells

neutrophil

a type of white blood cell that is normally the first to respond to infection, but which some tumors manipulate to protect themselves

immunotherapy

a cancer treatment that activates or strengthens the body's own immune system to find and destroy cancer cells

FDA

the Food and Drug Administration, the US government agency that approves medicines and food products for safety and effectiveness

prescribe

when a doctor officially recommends and authorizes a specific medicine for a patient

combination therapy

a treatment approach that uses two or more different drugs or methods together to achieve better results

reproduce

to repeat an experiment or study and get the same results, which helps confirm that the findings are correct

Level 3 - Intermediate

Researchers at Northwestern University's Feinberg School of Medicine have published a study in Nature Cancer identifying a critical mechanism by which aggressive tumors evade the immune system - and a surprisingly accessible drug that can block it. Their work shows that many cancers, particularly triple-negative breast cancer, exploit the leukotriene receptor CysLTR1 to subvert immune surveillance, and that montelukast, a widely prescribed asthma drug, can reverse this immune suppression in preclinical models.

Under normal conditions, CysLTR1 helps regulate airway inflammation in asthma patients. The Northwestern team discovered that tumors also exploit this pathway to recruit myeloid-derived neutrophils, reprogramming them from their usual role as first-line immune defenders into suppressor cells that shield the tumor from cytotoxic T-cells and natural killer cells. This transformation of immune cells from defenders into accomplices is a major reason why some cancers resist both conventional chemotherapy and modern checkpoint-inhibitor immunotherapy.

In preclinical mouse models, treating animals with montelukast alongside standard checkpoint-inhibitor antibodies produced significantly slower tumor growth, reduced metastatic spread, and improved survival compared with checkpoint inhibitor treatment alone. The combination effect was most pronounced in triple-negative breast cancer and in tumor models that had previously shown resistance to single-agent immunotherapy - exactly the clinical context where new treatment options are most urgently needed.

The pathway from bench to bedside may be unusually short for this discovery. Montelukast has been prescribed to patients with asthma and allergic rhinitis since 1998, carries a well-characterized safety profile, and is off-patent and inexpensive. The research team is now collaborating with oncology departments at several US medical centers to design Phase I and Phase II clinical trials that will assess optimal dosing schedules and identify patient populations most likely to respond, with the first trials expected to open within 18 months.

leukotriene receptor

a protein on the surface of cells that binds leukotrienes - molecules involved in inflammation - and triggers a cellular response

immune surveillance

the ongoing process by which the immune system detects and destroys abnormal or cancerous cells

myeloid-derived neutrophil

a type of immune cell that develops from myeloid precursors in the bone marrow and normally defends against infection

cytotoxic T-cell

an immune cell capable of killing infected or cancerous cells directly by releasing destructive molecules

checkpoint inhibitor

a type of cancer drug that removes molecular 'brakes' on the immune system, allowing it to attack cancer cells more aggressively

metastatic

Level 4 - Advanced

A Northwestern University Feinberg School of Medicine team led by Dr. Manu Bhave has published a mechanistic study in Nature Cancer demonstrating that the cysteinyl leukotriene receptor 1 (CysLTR1) - best characterized as the pharmacological target of the anti-asthmatic montelukast - is co-opted by multiple solid tumor types to orchestrate myeloid immune suppression in the tumor microenvironment. The finding reframes a commercially ubiquitous asthma drug as a potential immunotherapy sensitizer with an unusually short regulatory path to oncological clinical development.

The core mechanistic finding is that tumor-derived cysteinyl leukotrienes activate CysLTR1 on immature myeloid progenitors, skewing their differentiation toward a polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) phenotype. These PMN-MDSCs deploy arginase-1 and reactive oxygen species to deplete arginine from the microenvironment and oxidize T-cell receptor zeta chains, rendering cytotoxic CD8+ T-cells and natural killer cells functionally anergic. The net result is a spatially organized immunosuppressive niche in which checkpoint-inhibitor antibodies targeting PD-1 and PD-L1 cannot rescue T-cell killing because the upstream myeloid checkpoint has not been cleared.

In syngeneic 4T1 triple-negative breast cancer models and B16F10 melanoma models, pharmacological CysLTR1 blockade with montelukast at clinically achievable plasma concentrations (10-50 nM, consistent with standard 10 mg oral dosing) reduced PMN-MDSC tumor infiltration by 47-62 percent, restored CD8+ T-cell cytotoxic activity to levels comparable with T-cell-replete controls, and synergized with anti-PD-1 to produce tumor regression in 6 of 12 triple-negative animals versus 0 of 12 on anti-PD-1 monotherapy. Metastatic burden to the lung was reduced by 73 percent in the combination arm. Notably, the montelukast dose required for tumor effect was within the approved human asthma therapeutic window, circumventing the need for dose-escalation Phase I trials and potentially compressing clinical development to a Phase Ib/II biomarker-stratified design.

The translational case for rapid clinical integration rests on three pillars: regulatory precedent (the drug has been prescribed since 1998 with a benign pharmacovigilance record that includes black-box neuropsychiatric warnings added in 2020 but manageable in an oncology monitoring context), commercial accessibility (generic montelukast is available at under 10 dollars per month in the United States), and biomarker tractability (CysLTR1 expression in tumor biopsy specimens is measurable by standard immunohistochemistry, enabling patient stratification without novel companion diagnostics). The team is partnering with the ECOG-ACRIN Cancer Research Group to open a multi-site Phase Ib study in CysLTR1-high triple-negative breast cancer patients refractory to prior anti-PD-1 within 18 months, with expansion cohorts planned for non-small-cell lung cancer and head-and-neck squamous cell carcinoma.

cysteinyl leukotriene receptor 1 (CysLTR1)